Comparative Bioavailability Study of Ramipril, Amlodipine, and Indapamide in Hypertension: Single-Dose, Randomized, Crossover in Healthy Volunteers

The primary objective of this study is to evaluate the **bioavailability** of a combination product containing **ramipril**, **amlodipine**, and **indapamide** compared to the reference products: Triatec® 10 mg capsules, Norvasc® 10 mg tablets, and Natrilix® 2.5 mg film-coated tablets. This evaluation is conducted in healthy male and female volunteers under fasting conditions. The clinical relevance of this study lies in determining the pharmacokinetic profile of the combination product, which is essential for ensuring its efficacy and safety in the management of **hypertension**. No secondary objectives are provided.

The clinical trial involves participants diagnosed with **hypertension**. The study population includes both male and female subjects, with an age range category code of 3, which typically corresponds to adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected without specific mention of lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed as a **randomized**, two-period, two-sequence, crossover study to evaluate the comparative bioavailability of formulations containing **ramipril**, **amlodipine**, and **indapamide** in a combination product versus the reference products Triatec® 10 mg capsules, Norvasc® 10 mg tablets, and Natrilix® 2.5 mg film-coated tablets. The study will be conducted under fasting conditions in healthy male and female volunteers. The trial is categorized as a Phase 2 study and is expected to commence recruitment on August 12, 2024, with an estimated completion date of October 1, 2024.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into one of the two sequences for the crossover design. Each participant will receive a single dose of the test formulation and the reference products in separate periods, with a washout period in between to prevent carryover effects. Follow-up visits will be scheduled to monitor the participants' health status and collect necessary pharmacokinetic data. The end-of-study visit will conclude the trial, where final assessments will be conducted to ensure participant safety and gather any remaining data.

The expected length of participant involvement is determined by the duration of the crossover periods and the washout interval, typically spanning several weeks. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the bioavailability of the combination product compared to the reference formulations in the context of treating **hypertension**.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Therefore, a description of these elements is not possible based on the current data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in this description.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on August 12, 2024, with an estimated completion date of October 1, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards to evaluate the efficacy of the intervention under investigation, ensuring that the results are scientifically valid and reliable.